Bruno C Odisio1, Suguru Yamashita2, Steven Y Huang3, Scott E Kopetz4, Kamran Ahrar3, Takashi Mizuno2, Claudius Conrad2, Thomas A Aloia2, Yun Shin Chun2, Sanjay Gupta3, Jean-Nicolas Vauthey2. 1. Department of Interventional Radiology, The University of Texas MD Anderson Cancer Center, 1400 Pressler St., Unit 1471, Houston, TX 77030. Electronic address: bcodisio@mdanderson.org. 2. Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, 1400 Pressler St., Unit 1471, Houston, TX 77030. 3. Department of Interventional Radiology, The University of Texas MD Anderson Cancer Center, 1400 Pressler St., Unit 1471, Houston, TX 77030. 4. Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, 1400 Pressler St., Unit 1471, Houston, TX 77030.
Abstract
PURPOSE: To test the hypothesis that, given the current resection eligibility criteria for colorectal liver metastasis (CLM), prior hepatectomy would be associated with improved local tumor control and survival after percutaneous ablation of CLMs. MATERIALS AND METHODS: This single-institution retrospective study included 82 consecutive patients with 97 CLMs treated with ablation (radiofrequency ablation, microwave ablation, or cryoablation) from January 2005 to December 2014. Local tumor progression-free survival (LTPFS), recurrence-free survival (RFS) at any organ, and overall survival (OS) were calculated using the Kaplan-Meier method from the time of ablation and compared between patients with (n = 49) and without (n = 33) prior hepatectomy. Cox regression models were used to identify LTPFS predictors. RESULTS: Median overall follow-up period was 28 months (range, 4.5-132 months). Three-year actuarial LTPFS (patient level: 73% vs 34%, P < .001) was significantly higher in patients with than without prior hepatectomy, respectively. Similarly, 3-year RFS (23% vs 9.1%, P = .026) and OS (78% vs 48%, P = .003) were improved in patients with prior hepatectomy. At multivariate analysis, predictors of worse LTPFS were: no prior hepatectomy (hazard ratio [HR] 2.35, 95% confidence interval [CI] 1.02-5.45; P = .045), minimal ablation margin < 5 mm (HR 2.4, 95% CI 1.18-4.87; P = .016), and RAS-mutant tumor (HR 2.65, 95% CI 1.18-5.94; P = .019). CONCLUSIONS: Prior hepatectomy for CLMs is associated with improved local tumor control after percutaneous ablation of post-resection-developed CLMs.
PURPOSE: To test the hypothesis that, given the current resection eligibility criteria for colorectal liver metastasis (CLM), prior hepatectomy would be associated with improved local tumor control and survival after percutaneous ablation of CLMs. MATERIALS AND METHODS: This single-institution retrospective study included 82 consecutive patients with 97 CLMs treated with ablation (radiofrequency ablation, microwave ablation, or cryoablation) from January 2005 to December 2014. Local tumor progression-free survival (LTPFS), recurrence-free survival (RFS) at any organ, and overall survival (OS) were calculated using the Kaplan-Meier method from the time of ablation and compared between patients with (n = 49) and without (n = 33) prior hepatectomy. Cox regression models were used to identify LTPFS predictors. RESULTS: Median overall follow-up period was 28 months (range, 4.5-132 months). Three-year actuarial LTPFS (patient level: 73% vs 34%, P < .001) was significantly higher in patients with than without prior hepatectomy, respectively. Similarly, 3-year RFS (23% vs 9.1%, P = .026) and OS (78% vs 48%, P = .003) were improved in patients with prior hepatectomy. At multivariate analysis, predictors of worse LTPFS were: no prior hepatectomy (hazard ratio [HR] 2.35, 95% confidence interval [CI] 1.02-5.45; P = .045), minimal ablation margin < 5 mm (HR 2.4, 95% CI 1.18-4.87; P = .016), and RAS-mutant tumor (HR 2.65, 95% CI 1.18-5.94; P = .019). CONCLUSIONS: Prior hepatectomy for CLMs is associated with improved local tumor control after percutaneous ablation of post-resection-developed CLMs.
Authors: Scott Kopetz; George J Chang; Michael J Overman; Cathy Eng; Daniel J Sargent; David W Larson; Axel Grothey; Jean-Nicolas Vauthey; David M Nagorney; Robert R McWilliams Journal: J Clin Oncol Date: 2009-05-26 Impact factor: 44.544
Authors: Bernard Nordlinger; Halfdan Sorbye; Bengt Glimelius; Graeme J Poston; Peter M Schlag; Philippe Rougier; Wolf O Bechstein; John N Primrose; Euan T Walpole; Meg Finch-Jones; Daniel Jaeck; Darius Mirza; Rowan W Parks; Murielle Mauer; Erik Tanis; Eric Van Cutsem; Werner Scheithauer; Thomas Gruenberger Journal: Lancet Oncol Date: 2013-10-11 Impact factor: 41.316
Authors: Muneeb Ahmed; Luigi Solbiati; Christopher L Brace; David J Breen; Matthew R Callstrom; J William Charboneau; Min-Hua Chen; Byung Ihn Choi; Thierry de Baère; Gerald D Dodd; Damian E Dupuy; Debra A Gervais; David Gianfelice; Alice R Gillams; Fred T Lee; Edward Leen; Riccardo Lencioni; Peter J Littrup; Tito Livraghi; David S Lu; John P McGahan; Maria Franca Meloni; Boris Nikolic; Philippe L Pereira; Ping Liang; Hyunchul Rhim; Steven C Rose; Riad Salem; Constantinos T Sofocleous; Stephen B Solomon; Michael C Soulen; Masatoshi Tanaka; Thomas J Vogl; Bradford J Wood; S Nahum Goldberg Journal: J Vasc Interv Radiol Date: 2014-10-23 Impact factor: 3.464
Authors: Martina Wieser; Stefan Sauerland; Dirk Arnold; Wolff Schmiegel; Anke Reinacher-Schick Journal: BMC Cancer Date: 2010-06-21 Impact factor: 4.430
Authors: Dan G Blazer; Yoji Kishi; Dipen M Maru; Scott Kopetz; Yun Shin Chun; Michael J Overman; David Fogelman; Cathy Eng; David Z Chang; Huamin Wang; Daria Zorzi; Dario Ribero; Lee M Ellis; Katrina Y Glover; Robert A Wolff; Steven A Curley; Eddie K Abdalla; Jean-Nicolas Vauthey Journal: J Clin Oncol Date: 2008-10-20 Impact factor: 44.544
Authors: Jason W Denbo; Suguru Yamashita; Guillaume Passot; Michael Egger; Yun S Chun; Scott E Kopetz; Dipen Maru; Kristoffer Watten Brudvik; Steven H Wei; Claudius Conrad; Jean-Nicolas Vauthey; Thomas A Aloia Journal: J Gastrointest Surg Date: 2016-06-22 Impact factor: 3.452
Authors: Waleed Shady; Elena N Petre; Mithat Gonen; Joseph P Erinjeri; Karen T Brown; Anne M Covey; William Alago; Jeremy C Durack; Majid Maybody; Lynn A Brody; Robert H Siegelbaum; Michael I D'Angelica; William R Jarnagin; Stephen B Solomon; Nancy E Kemeny; Constantinos T Sofocleous Journal: Radiology Date: 2015-08-12 Impact factor: 11.105
Authors: Junichi Shindoh; Jean-Nicolas Vauthey; Giuzeppe Zimmitti; Steven A Curley; Steven Y Huang; Armeen Mahvash; Sanjay Gupta; Michael J Wallace; Thomas A Aloia Journal: J Am Coll Surg Date: 2013-04-28 Impact factor: 6.113
Authors: Theo Ruers; Frits Van Coevorden; Cornelis J A Punt; Jean-Pierre E N Pierie; Inne Borel-Rinkes; Jonathan A Ledermann; Graeme Poston; Wolf Bechstein; Marie-Ange Lentz; Murielle Mauer; Gunnar Folprecht; Eric Van Cutsem; Michel Ducreux; Bernard Nordlinger Journal: J Natl Cancer Inst Date: 2017-09-01 Impact factor: 11.816
Authors: Emily A Knott; Timothy J Ziemlewicz; Sam J Lubner; John F Swietlik; Sharon M Weber; Annie M Zlevor; Colin Longhurst; J Louis Hinshaw; Meghan G Lubner; Daniel L Mulkerin; Daniel E Abbott; Dustin Deming; Noelle K LoConte; Nataliya Uboha; Allison B Couillard; Shane A Wells; Paul F Laeseke; Marci L Alexander; Fred T Lee Journal: J Gastrointest Oncol Date: 2021-08
Authors: Lily V Saadat; Thomas Boerner; Debra A Goldman; Mithat Gonen; Timothy L Frankel; Efsevia Vakiani; T Peter Kingham; William R Jarnagin; Alice C Wei; Kevin C Soares; David B Solit; Michael I D'Angelica Journal: Ann Surg Oncol Date: 2020-07-18 Impact factor: 5.344
Authors: Simeon J S Ruiter; Pascale Tinguely; Iwan Paolucci; Jennie Engstrand; Daniel Candinas; Stefan Weber; Robbert J de Haas; Koert P de Jong; Jacob Freedman Journal: Front Oncol Date: 2021-11-15 Impact factor: 6.244